Literature DB >> 33535180

Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis.

Zhenglan Han1, Hanyan Wang1, Dongmei Guo1, Jingping Zhang1.   

Abstract

This study aimed to investigate the therapeutic mechanism of Huankuile suspension (HKL), a typical traditional Chinese medicine, on ulcerative colitis (UC) in a rat model. UC model was established by 2,4,6-trinitrobenzene sulfonic acid (TNBS) enema. Then, the rats were randomly divided into three groups: water treated group, HKL treated group and 5- amino salicylic acid (5-ASA) treated group. After 7 days treatment, the histological score in the HKL treated group was comparable with those in the control group. qRT-PCR and western blot demonstrated that HKL could significantly decreased pro-inflammatory cytokines, including TNF-α, IL-1β and IL-6, while having less effect on anti-inflammatory cytokines, including IL-4 and IL-10. Transcriptomic analysis identified 670 differentially expressed genes (DEGs) between HKL treated UC rats and water treated UC rats. These DEGs were mostly related with immune response. Besides, metabonomic profile revealed 136 differential metabolites which were significantly enriched in "pyrimidine metabolism", "glutathione metabolism", "purine metabolism" and "citrate cycle". Finally, integrated analysis revealed that metabonomic pathways including "steroid hormone biosynthesis", "pyrimidine metabolism", "purine metabolism", and "glutathione metabolism" were altered by HKL at both transcriptomic and metabonomic levels. HKL could inhibit inflammation and regulate bile metabolism, pyrimidine metabolism, purine metabolism, glutathione metabolism and citrate cycle.

Entities:  

Keywords:  Huankuile suspension; metabonomic; traditional Chinese medicine; transcriptomic; ulcerative colitis

Year:  2021        PMID: 33535180      PMCID: PMC7950284          DOI: 10.18632/aging.202427

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  54 in total

Review 1.  Nonbiological therapeutic management of ulcerative colitis.

Authors:  Nicolò Mezzina; Sophia Elizabeth Campbell Davies; Sandro Ardizzone
Journal:  Expert Opin Pharmacother       Date:  2018-09-27       Impact factor: 3.889

2.  Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.

Authors:  Ryuichi Yamamoto; Kouhei Muroi; Hiromasa Imaishi
Journal:  Chem Biol Interact       Date:  2018-05-26       Impact factor: 5.192

Review 3.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

4.  Critical role of IL-17 receptor signaling in acute TNBS-induced colitis.

Authors:  Zili Zhang; Mingquan Zheng; Julie Bindas; Paul Schwarzenberger; Jay K Kolls
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

5.  GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis.

Authors:  Makoto Ooi; Shin Nishiumi; Tomoo Yoshie; Yuuki Shiomi; Michitaka Kohashi; Ken Fukunaga; Shiro Nakamura; Takayuki Matsumoto; Naoya Hatano; Masakazu Shinohara; Yasuhiro Irino; Tadaomi Takenawa; Takeshi Azuma; Masaru Yoshida
Journal:  Inflamm Res       Date:  2011-04-27       Impact factor: 4.575

Review 6.  Pharmacotherapy of ulcerative colitis - current status and emerging trends.

Authors:  Hilal Ahmad; Vijay L Kumar
Journal:  J Basic Clin Physiol Pharmacol       Date:  2018-11-27

7.  Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease.

Authors:  Ann E Ostvik; Atle vB Granlund; Bjørn I Gustafsson; Sverre H Torp; Terje Espevik; Tom E Mollnes; Jan K Damås; Arne K Sandvik
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

8.  Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis.

Authors:  Ellen C Ebert; Xin Geng; Jim Lin; Kiron M Das
Journal:  Cell Immunol       Date:  2007-04-09       Impact factor: 4.868

Review 9.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  Craig Mowat; Andrew Cole; Al Windsor; Tariq Ahmad; Ian Arnott; Richard Driscoll; Sally Mitton; Tim Orchard; Matt Rutter; Lisa Younge; Charlie Lees; Gwo-Tzer Ho; Jack Satsangi; Stuart Bloom
Journal:  Gut       Date:  2011-05       Impact factor: 23.059

10.  Uygur medicine Xipayi Kui Jie'an affects gene expression profiles in intestinal tissue lesions in a rat model of ulcerative colitis.

Authors:  Kurexi Yunusi; Jingping Zhang; Li Zhong; Gulinisha Mosha; Ajiguli Nuermaimaiti; Mairipaiti Abudula; Halmurat Upur
Journal:  BMC Complement Altern Med       Date:  2015-05-22       Impact factor: 3.659

View more
  1 in total

Review 1.  Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment.

Authors:  Shuo Yuan; Qi Wang; Jiao Li; Jia-Chen Xue; You Li; Huan Meng; Xiao-Ting Hou; Ji-Xing Nan; Qing-Gao Zhang
Journal:  Chin Med       Date:  2022-06-18       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.